Literature DB >> 11369638

Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer.

P Kaliński1, P L Vieira, J H Schuitemaker, E C de Jong, M L Kapsenberg.   

Abstract

Interleukin-12 p70 (IL-12p70) heterodimer, composed of p35 and p40 subunits, is a major Th1-driving cytokine, promoting cell-mediated immunity. In contrast, IL-12p40 homodimer, secreted by APC in the absence of p35 expression, and free p40 monomer do not mediate IL-12 activity but act as IL-12 antagonists. Here it is reported that prostaglandin E(2) (PGE(2)), an inflammatory mediator with a previously known Th2-driving function, dose-dependently enhances the IL-12p40 mRNA expression and the secretion of IL-12p40 protein in human tumor necrosis factor-alpha (TNFalpha)-stimulated immature dendritic cells (DCs). This effect is selective and is not accompanied by the induction of IL-12p35 expression or by secretion of IL-12p70 heterodimer. Inability of TNFalpha/PGE(2) to induce IL-12p70 was not compensated by interferon gamma (IFNgamma), which strongly enhanced the lipopolysaccharide (LPS)-induced IL-12p70 production. In addition to the selective induction of IL-12p40 in TNFalpha-stimulated DCs, PGE(2) inhibited the production of IL-12p70 and IL-12p40 in DCs stimulated with LPS or CD40 ligand. These data suggest an additional level of the Th2-promoting activity of PGE(2), via selective induction of IL-12p40. Selective induction of IL-12p40 and suppression of bioactive IL-12p70 may have negative impact on anticancer vaccination with PGE(2)-matured DCs. (Blood. 2001;97:3466-3469)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369638     DOI: 10.1182/blood.v97.11.3466

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  100 in total

Review 1.  Anti-HER2 vaccines: new prospects for breast cancer therapy.

Authors:  Maha Zohra Ladjemi; William Jacot; Thierry Chardès; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Cancer Immunol Immunother       Date:  2010-06-08       Impact factor: 6.968

Review 2.  Epithelial crosstalk at the microbiota-mucosal interface.

Authors:  Jerry M Wells; Oriana Rossi; Marjolein Meijerink; Peter van Baarlen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-08       Impact factor: 11.205

3.  Plasma cytokine changes in relation to exercise intensity and muscle damage.

Authors:  Jonathan M Peake; Katsuhiko Suzuki; Matthew Hordern; Gary Wilson; Kazunori Nosaka; Jeff S Coombes
Journal:  Eur J Appl Physiol       Date:  2005-09-06       Impact factor: 3.078

Review 4.  The role of dendritic cells in cancer.

Authors:  Morten Hansen; Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2016-09-16       Impact factor: 9.623

Review 5.  Translating tumor antigens into cancer vaccines.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 6.  Functional diversity and plasticity of human dendritic cell subsets.

Authors:  Tomoki Ito; Yong-Jun Liu; Norimitsu Kadowaki
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

Review 7.  Toward effective immunotherapy for the treatment of malignant brain tumors.

Authors:  Duane A Mitchell; John H Sampson
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 8.  Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4.

Authors:  Pawel Kalinski
Journal:  Curr Opin Investig Drugs       Date:  2009-06

9.  Combined treatment with interleukin-12 and indomethacin promotes increased resistance in BALB/c mice with established Leishmania major infections.

Authors:  Jian Li; Udaikumar M Padigel; Phillip Scott; Jay P Farrell
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Infection with Francisella tularensis LVS clpB leads to an altered yet protective immune response.

Authors:  Lydia M Barrigan; Shraddha Tuladhar; Jason C Brunton; Matthew D Woolard; Ching-ju Chen; Divey Saini; Richard Frothingham; Gregory D Sempowski; Thomas H Kawula; Jeffrey A Frelinger
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.